

Applicants : Bradley T. Messmer, Nicholas Chiorazzi and Emilia Albesiano  
Application No. : 10/575,671  
Filing Date : July 25, 2008  
Page 3 of 6

### Claim Amendments

A listing of the claims, including Claims 16, 24, 36, 37, 52, 58, 76, 77, 82, 87-96 and 104 as currently canceled and new Claims 117-135 as added, is set forth below.

1-116. (Canceled)

117. (New) A method of

(a) determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells, or

(b) following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells,

the method comprising determining whether the B cell receptors on the B-CLL cells are encoded by antibody genes comprising a light chain antibody gene and a heavy chain antibody gene, wherein the light chain antibody gene and the heavy chain antibody gene are selected from the group consisting of V<sub>H</sub>4-39/D6-13/J<sub>H</sub>5/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set I), V<sub>H</sub>4-34/D5-5/J<sub>H</sub>6/V<sub>L</sub>κA17/J<sub>L</sub>κ1/κ2 (Set II), V<sub>H</sub>3-21/J<sub>H</sub>6/V<sub>L</sub>λ3h/J<sub>L</sub>λ3 (Set III), V<sub>H</sub>1-69/D3-16/J<sub>H</sub>3/V<sub>L</sub>κA27/J<sub>L</sub>κ1/κ4 (Set IV), V<sub>H</sub>1-69/D3-10/J<sub>H</sub>6/V<sub>L</sub>λ1c/J<sub>L</sub>λ1 (Set V), V<sub>H</sub>1-02/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIa), V<sub>H</sub>1-03/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIb), V<sub>H</sub>1-18/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1 (Set VIc), V<sub>H</sub>1-46/D6-19/J<sub>H</sub>4 (Set VId), V<sub>H</sub>5-51/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ2 (Set VIe), V<sub>H</sub>1-69/D3-3/J<sub>H</sub>4/V<sub>L</sub>κA19/J<sub>L</sub>κ4 (Set VII), and V<sub>H</sub>1-69/D2-2/J<sub>H</sub>6/V<sub>L</sub>κL6/2/J<sub>L</sub>κ3 (Set VIII), wherein if the B cell receptors on the B-CLL cells have an idiotype encoded by the antibody genes, the patient has a form of B-CLL susceptible to the treatment or the treatment of the patient has not eliminated the B-CLL cells.

118. (New) The method of claim 117, for determining whether a patient with B cell chronic lymphocytic leukemia (B-CLL) has a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

Applicants : Bradley T. Messmer, Nicholas Chiorazzi and Emilia Albesiano  
Application No. : 10/575,671  
Filing Date : July 25, 2008  
Page 4 of 6

119. (New) The method of claim 117, for following the progression of treatment of B-CLL in a patient having a form of B-CLL susceptible to treatment directed to eliminating idiotype-specific B cell receptor-bearing B-CLL cells.

120. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>4-39/D6-13/J<sub>H</sub>5/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set I).

121. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>4-34/D5-5/J<sub>H</sub>6/V<sub>L</sub>κA17/J<sub>L</sub>κ1/κ2 (Set II).

122. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>3-21/J<sub>H</sub>6/V<sub>L</sub>λ3h/J<sub>L</sub>λ3 (Set III).

123. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D3-16/J<sub>H</sub>3/V<sub>L</sub>κA27/J<sub>L</sub>κ1/κ4 (Set IV).

124. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D3-10/J<sub>H</sub>6/V<sub>L</sub>λ1c/J<sub>L</sub>λ1 (Set V).

125. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-02/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIa).

126. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-03/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1/κ2 (Set VIb).

127. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-18/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ1 (Set VIc).

128. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-46/D6-19/J<sub>H</sub>4 (Set VId).

129. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>5-51/D6-19/J<sub>H</sub>4/V<sub>L</sub>κO12/2/J<sub>L</sub>κ2 (Set VIe).

Applicants : Bradley T. Messmer, Nicholas Chiorazzi and Emilia Albesiano  
Application No. : 10/575,671  
Filing Date : July 25, 2008  
Page 5 of 6

130. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D3-3/J<sub>H</sub>4/V<sub>L</sub>κA19/J<sub>L</sub>κ4 (Set VII).

131. (New) The method of claim 117, wherein the light chain antibody gene and the heavy chain antibody gene is V<sub>H</sub>1-69/D2-2/J<sub>H</sub>6/V<sub>L</sub>κL6/2/J<sub>L</sub>κ3 (Set VIII).

132. (New) The method of claim 117, wherein the patient is pre-leukemic.

133. (New) The method of claim 117, wherein the patient is in an early leukemic state.

134. (New) The method of claim 117, wherein the patient is in a frank leukemic state.

135. (New) The method of claim 117, wherein the B-CLL cells from blood of the patient are evaluated.